Barrettʼs esophagus – screening or surveillance, and what about the quality of endoscopy?

• References

• 1 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEJM 2011; 365: 1375-1383
• 2 Bisschops R, Areia M, Coron E. et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2016; 48: 843-864
• 3 Abrams JA, Kapel RC, Lindberg GM. et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009; 7: 736-742 ; quiz 710
• 4 Desai M, Lieberman D, Srinivasan S. et al. Post-endoscopy Barrett´s neoplasia after a negative index endoscopy: a systematic review and proposals for definitions and performance measures in endoscopy. Endoscopy 2022; 54: 881-889
• 5 Wani S, Yadlapati R, Singh S. et al. Post-endoscopy esophageal neoplasia in Barrett's esophagus: Consensus statements from an International Expert Panel. Gastroenterology 2022; 162: 366-372
• 6 Parasa S, Desai M, Vittal A. et al. Estimating neoplasia detection rate (NDR) in patients with Barrett's oesophagus based on index endoscopy: a systematic review and meta-analysis. Gut 2019; 68: 2122-2128
• 7 Dhaliwal L, Codipilly DC, Gandhi P. et al. Neoplasia detection rate in Barrett's esophagus and its impact on missed dysplasia: results from a large population-based database. Clin Gastroenterol Hepatol 2021; 19: 922-929.e1
• 8 Vajravelu RK, Kolb JM, Thanawala SU. et al. Characterization of prevalent, post-endoscopy, and incident esophageal cancer in the United States: A large retrospective cohort study. Clin Gastroenterol Hepatol 2021;
• 9 Sawas T, Majzoub AM, Haddad J. et al. Magnitude and time-trend analysis of postendoscopy esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; 20: e31-e50